文献速递细胞病理与分子病理胸部病理

CAP细胞病理委员会呼吸系统非妇科细胞学实验室实践调查

Current Practices in Laboratories With Respiratory Nongynecologic Cytology Specimens: A Survey by the College of American Pathologists Cytopathology Committee.
PubMed 文献 · Arch Pathol Lab Med · 2026-08-03

美国病理学家学会细胞病理委员会于2013年首次调查后再次向1979家实验室发放问卷,了解呼吸系统细胞学实践现状。结果显示EBUS-FNA成为最常处理和判读的标本及最常进行的术中评估,免疫组化panel和分子检测广泛开展,但仅半数机构验证了免疫组化染色,部分机构对验证情况不确定。作者认为辅助检测验证和分子检测方面可能需要指南标准化。

要点

  • EBUS-FNA已成为最常处理和判读的呼吸细胞学标本及最常术中评估方式。
  • 非小细胞癌免疫组化panel较单染更常用,分子检测多外送。
  • 仅半数机构验证免疫组化染色,部分机构对验证情况不确定。

核心结论

  • 呼吸细胞学领域较十年前有显著进步,但辅助检测验证和分子检测方面可能需要指南来标准化实践并确保质量。

研究设计与样本

  • 美国病理学家学会细胞病理委员会向1979家实验室邮寄调查问卷,为2013年首次调查的后续研究。

主要发现

  • 呼吸细胞学需求高,EBUS-FNA成为最常处理和判读的标本之一及最常进行的术中评估。
  • 术中评估主要由病理医师单独完成,其次为细胞技术员单独完成。
  • 区分非小细胞癌的免疫组化最常用p63、CK5/6和p40(鳞癌)或TTF-1和Napsin A(腺癌)panel,较单染更常见。
  • 非小细胞肺癌分子检测常开展,多数外送实验室。
  • 免疫组化染色仅半数机构验证,较多机构对验证情况不确定。

关键数值与推荐

  • 区分鳞癌最常用p63、CK5/6和p40 panel,腺癌最常用TTF-1和Napsin A panel。
  • 免疫组化染色在半数机构中经过验证。
  • 分子检测多数发送至外部实验室进行。

临床怎么用

  • 呼吸细胞学实验室应关注EBUS-FNA标本处理和术中评估配置。
  • 非小细胞癌分型推荐使用免疫组化panel而非单染。
  • 应建立并记录细胞学辅助检测的验证流程,分子检测外送时需规范衔接。

局限性

  • 调查问卷方法依赖实验室自报,可能存在回忆偏倚。
  • 部分机构对免疫组化验证情况不确定,影响验证率准确性。
  • 摘要未报告问卷回收率及具体样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: In 2013, the Cytopathology Committee of the College of American Pathologists conducted its first survey on the practice patterns of laboratories performing respiratory cytology. OBJECTIVE.—: To capture current laboratory practices, recognize changes in respiratory cytopathology practices over the last decade, and provide insight into future directions for improvement. DESIGN.—: The survey was mailed to 1979 laboratories. RESULTS.—: The survey results show a high demand for respiratory cytology. There has been a shift regarding the preferred technique to endobronchial ultrasound-guided fine-needle aspirations as one of the most frequently processed and interpreted specimens, and the most commonly performed intraprocedural assessments. The pathologist alone mostly performed intraprocedural assessments, followed by the cytotechnologist alone. The immunostaining markers used to differentiate non-small carcinomas were most commonly the panel p63, CK5/6, and p40 for squamous cell carcinoma or TTF-1 and Napsin A for adenocarcinoma, compared with a single stain for either. Molecular testing for non-small cell lung carcinomas was commonly performed, with most molecular testing being sent to an outside laboratory. Immunohistochemical stains were validated in half of the institutions, with a high number responding that they were unsure of the validation performed in their laboratories. CONCLUSIONS.—: This follow-up study of our original study has shown significant advances in the field of respiratory cytology. The data also showed a few areas, specifically validation of cytology preparations for ancillary testing and molecular testing, which may benefit from guidelines to standardize cytopathology practice and ensure quality care.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Nguyen LN, King A, Souers RJ, et al. Current Practices in Laboratories With Respiratory Nongynecologic Cytology Specimens: A Survey by the College of American Pathologists Cytopathology Committee. Arch Pathol Lab Med. 2026. PMID: 42547077. doi:10.5858/arpa.2025-0225-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。